Results 61 to 70 of about 17,963 (297)

Quality of life in Prolactinoma: A systematic review

Pituitary
Background Prolactinomas are common tumours that significantly reduce quality-of-life (QOL) due to sellar mass effect, secondary hypogonadism, and the peripheral effects of prolactin.
Mendel Castle-Kirszbaum, N. Biermasz, Jeremy Kam, T. Goldschlager   +3 more
semanticscholar   +1 more source

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report

Journal of Medical Case Reports, 2019
Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi, Yukiko Nakahara, Ryo Ebashi, Atsushi Ogata, Shoko Shimokawa, Jun Masuoka, Tatsuya Abe   +6 more
doaj   +1 more source

Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1

Frontiers in Endocrinology, 2019
Context: Overall, giant prolactinomas are rare tumors (4%), especially those larger than 60 mm (1%). Despite the predominance of macroadenoma documented in multiple endocrine neoplasia type 1 (MEN1)-related prolactinoma, only three giant prolactinoma ...
Naiara C. B. Dantas, Carlos E. L. Soares, Manoel R. A. Martins, Delmar M. Lourenço, Delmar M. Lourenço, Ana R. P. Quidute, Ana R. P. Quidute   +6 more
doaj   +1 more source

Aggressive giant prolactinoma: a case report

Journal of Medical Case Reports, 2022
Background Managing treatment-resistant aggressive giant prolactinoma can be challenging, as the diagnosis is often complex, and treatment beyond dopamine agonists, surgery, and radiotherapy is limited.
Marisa Khatijah Borhan, Florence Hui Sieng Tan   +1 more
doaj   +1 more source

Male, Female, Other: Transgender and the Impact in Primary Care [PDF]

, 2016
Transgender includes patients at various stages of their journey. It is important that providers care for transgender patients with a culturally sensitive approach, awareness, and competent skill. There are new terms to learn.
Markwick, Laura
core   +2 more sources

Increased Lipid Levels Improves after Treatment with Cabergolin in Patients with Prolactinoma

Medicine Science, 2015
It has been suggested that hyperprolactinemia may be associated with obesity and dyslipidemia. However it is not fully understood that dyslipidemia is occurs independently or due to obesity.
Mazhar Muslum Tuna, Bercem Aycicek Dogan, Mehtap Navdar Basaran, Ayse Arduc, Dilek Berker, Serdar Guler   +5 more
doaj   +1 more source

A giant invasive macroprolactinoma with recurrent nasal bleeding as the first clinical presentation: case report and review of literature

BMC Endocrine Disorders, 2023
Background Giant prolactinoma (> 4 cm in dimension) is a rare disorder. Invasive macroprolactinoma has the potential to cause base of skull erosion and extend into the nasal cavity or even the sphenoid sinus.
Danting Li, Yan Wang, Huiwen Tan, Peiqiong Luo, Yerong Yu   +4 more
doaj   +1 more source

Giant prolactinoma: case report and review of literature [PDF]

, 2013
“Invasive giant prolactinoma” is a large prolactinoma (>4 cm in dimension) presenting with serum prolactin levels of >1000 ng/dL and mass related clinical symptoms.
Bagher Larijani, Hamidreza Aghaei Meybodi, Masoud Rahmanian, Mohammad-reza Mohajeri-Tehrani   +3 more
core   +2 more sources

Clinical characteristics and presence of prolactinoma in women with hyperprolactinemia

Iatreia, 2016
Objectives: To clinically characterize women with hyperprolactinemia at InSer Pereira (Colombia) and to determine the prevalence of prolactinoma. Methods: Retrospective description of 45 patients with hyperprolactinemia, and contrasted pituitary magnetic
López-Clavijo, Carlos Alberto, Gaviria-Maya, Juan Esteban, Henao-Flórez, Rodrigo Eduardo, Piedrahíta-Gutiérrez, Dany Leandro   +3 more
doaj   +1 more source

Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors [PDF]

, 1997
The effects of somatostatin (SS-14 and/or SS-28) and of the three octapeptide SS-analogs that are available for clinical use (octreotide, BIM-23014 and RC-160) on hormone release by primary cultures of 15 clinically ...
Herder, W.W. (Wouter) de, Hofland, L.J. (Leo), Koetsveld, P.M. (Peter) van, Kros, J.M. (Johan), Lamberts, S.W.J. (Steven), Uffelen, C. van, Uitterlinden, P. (Piet), Visser-Wisselaar, H.A. (Heleen), Waaijers, M. (Marlijn), Zuyderwijk, J.   +9 more
core   +2 more sources